Cleanest way would be an issue to sophs for around $5-6m - keeps us going till launch underway and sp higher. Then a decision on timing of FDA approval project and whether company can fund out of cash flow or more equity - or blend of both.
DYOR
Accident prone, page-21
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)